articleTop 1% cited
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
The Lancet Oncology · 2018 · Vol. 19(11) · pp. 1480–1492
F. Stephen Hodi✉(Dana-Farber Cancer Institute)Vanna Chiarion‐Sileni(Istituto Oncologico Veneto)René González(University of Colorado Denver)Jean-Jacques Grob(Aix-Marseille Université)Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology)C. Lance Cowey(Texas Oncology)Christopher D. Lao(University of Michigan)Dirk Schadendorf(University of Duisburg-Essen)John Wagstaff(Swansea University)Reinhard Dummer(See-Spital)Pier Francesco Ferrucci(European Institute of Oncology)Michael SmylieAndrew Hill(Trans Tasman Radiation Oncology Group)David Hogg(Princess Margaret Cancer Centre)Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón)Joel Jiang(Bristol-Myers Squibb (United States))Jasmine I. Rizzo(Bristol-Myers Squibb (United States))James Larkin(Royal Marsden NHS Foundation Trust)Jedd D. Wolchok(Cornell University)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchMelanoma and MAPK PathwaysIpilimumabNivolumabMedicineInternal medicineOncologyImmunotherapyCancer
MeSH terms
Antineoplastic Agents, ImmunologicalIpilimumabNivolumabProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodHumansMelanomaMutationNeoplasm StagingSkin NeoplasmsTime FactorsBiomarkers, TumorProto-Oncogene Proteins B-raf
Funding
- Bristol-Myers Squibb
- Ono Pharmaceutical
- National Cancer Institute
Citations
1,386
FWCI
65.23
field-weighted impact
References
17
Percentile
100%
vs. same field & year
Citations per year
Cited by
Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology
Frontiers in Oncology · 2020 · 283 citations
Top 10 Challenges in Cancer Immunotherapy
Immunity · 2020 · 2,223 citations
References
Immune Checkpoint Blockade in Cancer Therapy
Journal of Clinical Oncology · 2015 · 2,706 citations
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Biometrics · 2000 · 2,856 citations
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Journal of Clinical Oncology · 2015 · 2,105 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.